Twist Bioscience misses earnings despite revenue beat

SOUTH SAN FRANCISCO, Calif. - On Monday, Twist Bioscience Corporation (NASDAQ:TWST) reported a second quarter fiscal 2026 loss of -$0.71 per share, missing analyst estimates of -$0.48 per share by $0.23. Revenue reached $110.72 million, exceeding the consensus estimate of $107.65 million.

Shares of the company edged down 0.48% in pre-market trading following the earnings announcement, reflecting investor concern over the bottom-line miss despite the top-line beat.

The synthetic biology company’s wider-than-expected loss overshadowed its revenue performance, which beat Wall Street expectations by approximately 2.9%.

"As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

The company, which provides customizable solutions across diagnostics, therapeutics, industrial, agriculture and research markets, delivered products including oligos, genes, proteins, libraries, and antibody discovery solutions during the quarter.

Twist Bioscience utilizes its proprietary silicon platform to manufacture synthetic DNA.

Twist Bioscience recently expanded its clonal genes portfolio with the early access launch of Complex Genes, targeting the growing nucleic acid therapeutics market.

The company positions itself as a mid-cap growth and value biotech company serving customers requiring precision at scale and speed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.